261 related articles for article (PubMed ID: 25897242)
1. Breast cancer therapy and cardiovascular risk: focus on trastuzumab.
Sandoo A; Kitas GD; Carmichael AR
Vasc Health Risk Manag; 2015; 11():223-8. PubMed ID: 25897242
[TBL] [Abstract][Full Text] [Related]
2. Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer.
Sandoo A; Kitas GD; Carmichael AR
Anticancer Res; 2014 Mar; 34(3):1147-51. PubMed ID: 24596352
[TBL] [Abstract][Full Text] [Related]
3. Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer.
Haq B; Geyer CE
Womens Health (Lond); 2009 Mar; 5(2):135-47. PubMed ID: 19245352
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity of novel HER2-targeted therapies.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
[TBL] [Abstract][Full Text] [Related]
5. Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
Yu AF; Yadav NU; Eaton AA; Lung BY; Thaler HT; Liu JE; Hudis CA; Dang CT; Steingart RM
Oncologist; 2015 Oct; 20(10):1105-10. PubMed ID: 26240135
[TBL] [Abstract][Full Text] [Related]
6. [Heart failure in women treated with adjuvant trastuzumab for breast cancer].
Tarantini L; Feola M; Albini A; Gori S; Foglietta J; Cicoira MA; Pulignano G
G Ital Cardiol (Rome); 2012 May; 13(5 Suppl 1):54S-62S. PubMed ID: 23678535
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.
Dokmanovic M; King KE; Mohan N; Endo Y; Wu WJ
Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):755-766. PubMed ID: 28571477
[TBL] [Abstract][Full Text] [Related]
8. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
9. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
10. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Hortobagyi GN
Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
[TBL] [Abstract][Full Text] [Related]
11. Breast Cancer and Heart Failure.
Almuwaqqat Z; Meisel JL; Barac A; Parashar S
Heart Fail Clin; 2019 Jan; 15(1):65-75. PubMed ID: 30449381
[TBL] [Abstract][Full Text] [Related]
12. Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab.
Lemieux J; Diorio C; Côté MA; Provencher L; Barabé F; Jacob S; St-Pierre C; Demers E; Tremblay-Lemay R; Nadeau-Larochelle C; Michaud A; Laflamme C
Anticancer Res; 2013 Jun; 33(6):2569-76. PubMed ID: 23749910
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab-Induced Cardiomyopathy.
Barish R; Gates E; Barac A
Cardiol Clin; 2019 Nov; 37(4):407-418. PubMed ID: 31587782
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab-based chemotherapy modulates systemic redox homeostasis in women with HER2-positive breast cancer.
Lemos LG; Victorino VJ; Herrera AC; Aranome AM; Cecchini AL; Simão AN; Panis C; Cecchini R
Int Immunopharmacol; 2015 Jul; 27(1):8-14. PubMed ID: 25937481
[TBL] [Abstract][Full Text] [Related]
15. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.
Chang HR
Cancer; 2010 Jun; 116(12):2856-67. PubMed ID: 20564392
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity associated with trastuzumab and chemotherapy used for HER2-positive cancers.
Mardis C
MLO Med Lab Obs; 2014 Apr; 46(4):18, 20. PubMed ID: 24783682
[No Abstract] [Full Text] [Related]
18. Monitoring Trastuzumab Resistance and Cardiotoxicity: A Tale of Personalized Medicine.
Dokmanovic M; Wu WJ
Adv Clin Chem; 2015; 70():95-130. PubMed ID: 26231486
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab in the Treatment of Breast Cancer.
Maximiano S; Magalhães P; Guerreiro MP; Morgado M
BioDrugs; 2016 Apr; 30(2):75-86. PubMed ID: 26892619
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
